Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
A Combination of Zarnestra With Velcade for Patients With Relapsed Multiple Myeloma
This study has been terminated.
( Initial Principal Investigator left Moffitt )
Study NCT00361088 Information provided by H. Lee Moffitt Cancer Center and Research Institute
First Received on August 3, 2006. Last Updated on May 25, 2011
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Multiple Myeloma
Additional conditions recognized in this trial
Neoplasms, Plasma Cell
More general conditions related to this trial
Blood Protein Disorders
Cardiovascular Diseases
Hematologic Diseases
Hemorrhagic Disorders
Hemostatic Disorders
Immune System Diseases
Immunoproliferative Disorders
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Paraproteinemias
Vascular Diseases
Interventions listed in this trial
PS-341
R11577
Additional drug interventions recognized in this trial
Bortezomib
Tipifarnib
More general drug interventions related to this trial
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protease Inhibitors
Therapeutic Uses
Sponsors listed in this trial
H. Lee Moffitt Cancer Center and Research Institute
Millennium Pharmaceuticals, Inc.
National Cancer Institute (NCI)
Back to top of Main Content
